文献速递肝病

原发性甲状腺功能减退症与代谢功能障碍相关脂肪性肝病之间的关联:一项更新的荟萃分析

Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
PubMed 文献 · Gut · 2024-08-08

原发性甲状腺功能减退症与MASLD患病风险升高相关(OR 1.43,95%CI 1.23-1.66),也与代谢功能障碍相关脂肪性肝炎或晚期纤维化风险升高相关(OR 2.84,95%CI 2.07-3.90)。纵向研究显示甲状腺功能减退与MASLD发病风险呈边缘性非显著关联(HR 1.39,95%CI 0.98-1.97)。

要点

  • 原发性甲状腺功能减退症与MASLD患病风险升高相关(OR 1.43,95%CI 1.23-1.66)。
  • 甲状腺功能减退与代谢功能障碍相关脂肪性肝炎或晚期纤维化风险升高相关(OR 2.84,95%CI 2.07-3.90)。
  • 纵向研究中甲状腺功能减退与MASLD发病风险呈边缘性非显著关联(HR 1.39,95%CI 0.98-1.97)。

核心结论

  • 这项大型更新的荟萃分析提供证据表明,原发性甲状腺功能减退症与MASLD的患病存在及组织学严重程度均显著相关。

研究设计与样本

  • 系统检索PubMed、Scopus和Web of Science从建库至2024年1月31日的观察性研究,MASLD通过肝活检、影像学或国际疾病分类编码诊断。
  • 采用随机效应模型进行荟萃分析。

主要发现

  • 原发性甲状腺功能减退症(定义为左甲状腺素替代治疗、亚临床甲状腺功能减退或明显甲状腺功能减退)与MASLD患病风险升高相关(24项研究;随机效应OR 1.43,95%CI 1.23至1.66;I²=89%)。
  • 甲状腺功能减退与代谢功能障碍相关脂肪性肝炎或晚期纤维化风险显著升高相关(5项研究;随机效应OR 2.84,95%CI 2.07至3.90;I²=0%)。
  • 4项纵向研究的荟萃分析显示,在中位4.5年随访期间,甲状腺功能减退与MASLD发病风险呈边缘性非显著关联(随机效应HR 1.39,95%CI 0.98至1.97;I²=85%)。
  • 敏感性分析未改变上述结果。
  • 漏斗图未显示任何显著发表偏倚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epidemiological studies have reported an association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the magnitude of the risk and whether this risk changes with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between primary hypothyroidism and the risk of MASLD. DESIGN: We systematically searched PubMed, Scopus and Web of Science from database inception to 31 January 2024, using predefined keywords to identify observational studies in which MASLD was diagnosed by liver biopsy, imaging or International Classification of Diseases codes. A meta-analysis was performed using random-effects modelling. RESULTS: We identified 24 cross-sectional and 4 longitudinal studies with aggregate data on ~76.5 million individuals. Primary hypothyroidism (defined as levothyroxine replacement treatment, subclinical hypothyroidism or overt hypothyroidism) was associated with an increased risk of prevalent MASLD (n=24 studies; random-effects OR 1.43, 95% CI 1.23 to 1.66; I2=89%). Hypothyroidism was also associated with a substantially higher risk of metabolic dysfunction-associated steatohepatitis or advanced fibrosis (n=5 studies; random-effects OR 2.84, 95% CI 2.07 to 3.90; I2=0%). Meta-analysis of data from four longitudinal studies showed that there was a marginally non-significant association between hypothyroidism and risk of developing MASLD over a median 4.5-year follow-up (random-effects HR 1.39, 95% CI 0.98 to 1.97; I2=85%). Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias. CONCLUSION: This large and updated meta-analysis provides evidence that primary hypothyroidism is significantly associated with both an increased presence of and histological severity of MASLD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Mantovani A, Csermely A, Bilson J, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut. 2024. PMID: 38782564. doi:10.1136/gutjnl-2024-332491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。